Tapewire

Nasdaq · USD

ATRA

Atara Biotherapeutics, Inc.

Export transactions ↓
Tapewire entity
6828
SEC CIK
0001604464
Parsed reports
491

Last 12 months

Inside the activity.

2 purchase rows · 18 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202505
Dec 202500
Jan 202601
Feb 202600
Mar 202608
Apr 202600
May 202613
Jun 202600
Jul 202600
Aug 202601
Sep 202610
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 12, 2016 Filed Oct 13, 2016 17:22 UTC
MCGRATH JOHNChief Financial Officer
SaleCommon Stock 2,500 $16.41 $41,025.00
Disclosure

SEC source: 0001209191-16-145821 · doc4.xml · nonDerivative · entry 2

MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,323

F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.35 to $16.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 11, 2016 Filed Oct 13, 2016 17:22 UTC
MCGRATH JOHNChief Financial Officer
SaleCommon Stock 2,500 $18.52 $46,300.00
Disclosure

SEC source: 0001209191-16-145821 · doc4.xml · nonDerivative · entry 1

MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,823

F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.

F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.30 to $18.675. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 28, 2016 Filed Sep 29, 2016 16:26 UTC
Ciechanover Isaac E.Director · Chief Executive Officer
SaleCommon Stock 300 $21.82 $6,546.00
Disclosure

SEC source: 0001209191-16-143144 · doc4.xml · nonDerivative · entry 3

Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 406,578

F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016.

Read SEC document
September 28, 2016 Filed Sep 29, 2016 16:26 UTC
Ciechanover Isaac E.Director · Chief Executive Officer
SaleCommon Stock 4,500 $21.40 $96,300.00
Disclosure

SEC source: 0001209191-16-143144 · doc4.xml · nonDerivative · entry 2

Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 406,878

F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016.

F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.81 to $21.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.

Read SEC document
September 27, 2016 Filed Sep 29, 2016 16:26 UTC
Ciechanover Isaac E.Director · Chief Executive Officer
SaleCommon Stock 7,200 $20.50 $147,600.00
Disclosure

SEC source: 0001209191-16-143144 · doc4.xml · nonDerivative · entry 1

Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 411,378

F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016.

F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.03 to $20.84. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.

Read SEC document
September 22, 2016 Filed Sep 23, 2016 19:25 UTC
Soffer GadChief Operating Officer
GrantCommon Stock 90,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-16-142707 · doc4.xml · nonDerivative · entry 1

Soffer Gad · CIK 0001612090 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,249

F1 · shares: These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years.

Read SEC document
September 22, 2016 Filed Sep 23, 2016 23:26 UTC
Haqq ChristopherChief Medical Officer
GrantCommon Stock 90,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-16-142708 · doc4.xml · nonDerivative · entry 1

Haqq Christopher · CIK 0001612095 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,948

F1 · shares: These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years.

Read SEC document
September 22, 2016 Filed Sep 23, 2016 19:25 UTC
Ciechanover Isaac E.Director · Chief Executive Officer
GrantCommon Stock 320,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-16-142706 · doc4.xml · nonDerivative · entry 1

Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 549,136

F1 · shares: These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years.

Read SEC document
September 22, 2016 Filed Sep 23, 2016 23:27 UTC
Turner Heather DVP, General Counsel & Sec.
GrantEmployee Stock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $20.46 $0.00
Disclosure

SEC source: 0001209191-16-142709 · doc4.xml · derivative · entry 1

Turner Heather D · CIK 0001403571 · VP, General Counsel & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2023-09-22

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares shall vest and become exercisable in equal monthly installments starting on the monthly anniversary of the date of grant of September 22, 2016.

Read SEC document
September 16, 2016 Filed Sep 19, 2016 17:13 UTC
Ciechanover Isaac E.Director · Chief Executive Officer
SaleCommon Stock 3,600 $19.32 $69,552.00
Disclosure

SEC source: 0001209191-16-142020 · doc4.xml · nonDerivative · entry 2

Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 418,578

F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016.

F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.00 to $19.94. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.

Read SEC document
September 15, 2016 Filed Sep 19, 2016 17:13 UTC
Ciechanover Isaac E.Director · Chief Executive Officer
SaleCommon Stock 3,600 $19.39 $69,804.00
Disclosure

SEC source: 0001209191-16-142020 · doc4.xml · nonDerivative · entry 1

Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 422,178

F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016.

F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.03 to $19.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.

Read SEC document
October 21, 2014 Filed Nov 8, 2018 21:07 UTC Amendment PurchaseCommon Stock 9,090 $11.00 $99,990.00
Disclosure

SEC source: 0001209191-18-057738 · doc4a.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,090

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.